Viola Poeschel, MD, discusses the results for the phase III FLYER trial in which the standard 6 cycles of R-CHOP were compared to a reduced 4 cycles of R-CHOP in patients with diffuse large B-cell lymphoma
Viola Poeschel, MD, a medical doctor at the Saarland University Medical School, discusses the results for the phase III FLYER trial in which the standard 6 cycles of R-CHOP were compared to a reduced 4 cycles of R-CHOP in patients with diffuse large B-cell lymphoma (DLBCL).
At 3-year follow-up, the standard regimen has a 94% progression-free survival rate compared to 96% with the reduced treatment with 4 cycles, Poeschel says. These data show the newer regimen is noninferior to the standard of care.
In regard to efficacy, both arms had similar event-free survival and no difference in overall survival, Poeschel adds. The 4 cycles of R-CHOP also reduced toxicity, where the 6-cycle regimen led to a higher hematologic toxicity profile. Poeschel notes that the total number of non-hematologic toxicities could be reduced by using only 4 cycles compared to the standard 6 cycles of R-CHOP.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More